Patents by Inventor Glenn Guerin

Glenn Guerin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
    Patent number: 9987286
    Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 5, 2018
    Assignees: EMBERA NEUROTHERAPEUTICS, INC., BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE
    Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
  • Compositions and Methods for the Treatment of Addiction, Psychiatric Disorders, and Neurodegenerative Disease
    Publication number: 20160038509
    Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
    Type: Application
    Filed: June 11, 2015
    Publication date: February 11, 2016
    Applicant: EMBERA NEUROTHERAPEUTICS, INC.
    Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
  • Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
    Patent number: 9078886
    Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: July 14, 2015
    Assignees: Embera Neurotherapeutics, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE
    Publication number: 20130303523
    Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
    Type: Application
    Filed: June 16, 2011
    Publication date: November 14, 2013
    Applicant: EMBERA NEUROTHERAPEUTICS, INC.
    Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin